Cargando…
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study
BACKGROUND: After more than 2 years of the pandemic, effective treatment for COVID-19 is still under research. In recent months, publications hypothesized amantadine's potential beneficial effect on SARS-CoV-2 infection. OBJECTIVE: To compare the groups of Parkinson's Disease (PD) patients...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724557/ https://www.ncbi.nlm.nih.gov/pubmed/36509028 http://dx.doi.org/10.1016/j.parkreldis.2022.105238 |
_version_ | 1784844445195173888 |
---|---|
author | Przytuła, Filip Kasprzak, Jakub Dulski, Jarosław Koziorowski, Dariusz Kwaśniak-Butowska, Magdalena Sołtan, Witold Roszmann, Anna Śmiłowska, Katarzyna Schinwelski, Michał Sławek, Jarosław |
author_facet | Przytuła, Filip Kasprzak, Jakub Dulski, Jarosław Koziorowski, Dariusz Kwaśniak-Butowska, Magdalena Sołtan, Witold Roszmann, Anna Śmiłowska, Katarzyna Schinwelski, Michał Sławek, Jarosław |
author_sort | Przytuła, Filip |
collection | PubMed |
description | BACKGROUND: After more than 2 years of the pandemic, effective treatment for COVID-19 is still under research. In recent months, publications hypothesized amantadine's potential beneficial effect on SARS-CoV-2 infection. OBJECTIVE: To compare the groups of Parkinson's Disease (PD) patients who were administered amantadine chronically and those who did not take this medication in the context of the incidence and severity of COVID-19 infection. METHODS: An observational, retrospective, multicenter cohort study was conducted among consecutive patients with idiopathic PD. The structured questionnaires were completed during the patient's follow-up visits at the Outpatient Clinic or during hospitalization. The questionnaire included the following informations: patient's age, duration of PD, Hoehn-Yahr (H–Y) stage, comorbidities, medications, COVID-19 confirmed by reverse transcription polymerase chain reaction (RT-PCR) swab test for SARS-CoV-2 with specified symptoms and their severity (home or hospital treatment). The vaccination status was verified as well. RESULTS: Five hundred fifty-two (n = 552) patients participated in the study - 329 men (60%). The mean H–Y stage was 2.44 (range: 1–4) and the mean duration of PD was 9.6 years (range: 1–34). One hundred four subjects (19%) had confirmed COVID-19 infection. Subjects over 50 years of age had a significantly lower incidence of COVID-19 (17% vs 38%, p = 0.0001) with difference also in mean H–Y stage (2.27 vs 2.49; p = 0.011) and disease duration (8.4 vs 9.9 years, p = 0.007). There were no differences between patients with and without co-morbidities. In the whole analyzed group 219 (40%) subjects were treated with amantadine. Comparing COVID-19 positive and negative patients, amantadine was used by 48/104 (46%) and 171/448 (38%) respectively. 22% of patients on amantadine vs. 17% of patients without amantadine developed COVID-19. These differences were not significant. There were no differences in morbidity and severity of COVID-19 between amantadine users and non-users as well. CONCLUSIONS: COVID-19 was less common in older (>50) with longer duration and more advanced patients. Amantadine did not affect the risk of developing COVID-19 or the severity of infection. |
format | Online Article Text |
id | pubmed-9724557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97245572022-12-06 Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study Przytuła, Filip Kasprzak, Jakub Dulski, Jarosław Koziorowski, Dariusz Kwaśniak-Butowska, Magdalena Sołtan, Witold Roszmann, Anna Śmiłowska, Katarzyna Schinwelski, Michał Sławek, Jarosław Parkinsonism Relat Disord Article BACKGROUND: After more than 2 years of the pandemic, effective treatment for COVID-19 is still under research. In recent months, publications hypothesized amantadine's potential beneficial effect on SARS-CoV-2 infection. OBJECTIVE: To compare the groups of Parkinson's Disease (PD) patients who were administered amantadine chronically and those who did not take this medication in the context of the incidence and severity of COVID-19 infection. METHODS: An observational, retrospective, multicenter cohort study was conducted among consecutive patients with idiopathic PD. The structured questionnaires were completed during the patient's follow-up visits at the Outpatient Clinic or during hospitalization. The questionnaire included the following informations: patient's age, duration of PD, Hoehn-Yahr (H–Y) stage, comorbidities, medications, COVID-19 confirmed by reverse transcription polymerase chain reaction (RT-PCR) swab test for SARS-CoV-2 with specified symptoms and their severity (home or hospital treatment). The vaccination status was verified as well. RESULTS: Five hundred fifty-two (n = 552) patients participated in the study - 329 men (60%). The mean H–Y stage was 2.44 (range: 1–4) and the mean duration of PD was 9.6 years (range: 1–34). One hundred four subjects (19%) had confirmed COVID-19 infection. Subjects over 50 years of age had a significantly lower incidence of COVID-19 (17% vs 38%, p = 0.0001) with difference also in mean H–Y stage (2.27 vs 2.49; p = 0.011) and disease duration (8.4 vs 9.9 years, p = 0.007). There were no differences between patients with and without co-morbidities. In the whole analyzed group 219 (40%) subjects were treated with amantadine. Comparing COVID-19 positive and negative patients, amantadine was used by 48/104 (46%) and 171/448 (38%) respectively. 22% of patients on amantadine vs. 17% of patients without amantadine developed COVID-19. These differences were not significant. There were no differences in morbidity and severity of COVID-19 between amantadine users and non-users as well. CONCLUSIONS: COVID-19 was less common in older (>50) with longer duration and more advanced patients. Amantadine did not affect the risk of developing COVID-19 or the severity of infection. Elsevier Ltd. 2023-01 2022-12-06 /pmc/articles/PMC9724557/ /pubmed/36509028 http://dx.doi.org/10.1016/j.parkreldis.2022.105238 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Przytuła, Filip Kasprzak, Jakub Dulski, Jarosław Koziorowski, Dariusz Kwaśniak-Butowska, Magdalena Sołtan, Witold Roszmann, Anna Śmiłowska, Katarzyna Schinwelski, Michał Sławek, Jarosław Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study |
title | Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study |
title_full | Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study |
title_fullStr | Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study |
title_full_unstemmed | Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study |
title_short | Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study |
title_sort | morbidity and severity of covid-19 in patients with parkinson's disease treated with amantadine - a multicenter, retrospective, observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724557/ https://www.ncbi.nlm.nih.gov/pubmed/36509028 http://dx.doi.org/10.1016/j.parkreldis.2022.105238 |
work_keys_str_mv | AT przytułafilip morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy AT kasprzakjakub morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy AT dulskijarosław morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy AT koziorowskidariusz morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy AT kwasniakbutowskamagdalena morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy AT sołtanwitold morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy AT roszmannanna morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy AT smiłowskakatarzyna morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy AT schinwelskimichał morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy AT sławekjarosław morbidityandseverityofcovid19inpatientswithparkinsonsdiseasetreatedwithamantadineamulticenterretrospectiveobservationalstudy |